Ad blocking detected

Thank you for visiting We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Ultra Club
$500/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

PharmaCielo Ltd. (V:PCLO)

Business Focus: Alternative Medicine

INK Edge Outlook

Insider Chart - Past 6 Months

Insider Filings

Latest 10 SEDI filings for PCLO within the last 6 months
See all filings within the past 6 months

Company News

Feb 08, 2023 06:30 ET
PharmaCielo Receives Purchase Order for API from Brazilian Pharmaceutical Company - Represents Third Customer in the Country
PharmaCielo has received a purchase order for CBD Isolate as an API, which will be used by a large pharmaceutical company in Brazil (the "Customer"), for final testing.The Customer has already qualified PharmaCielo as a supplier of API – the Company expects to begin shipping product on a commercial basis to the Customer by Q4 2023.TORONTO and RIONEGRO, Colombia , Feb. 8, 2023 /CNW/ - PharmaCielo Ltd. ("PharmaCielo" or the "Company") (TSXV: PCLO) (OTCQX: PCLOF), the Canadian parent of Colombia's premier cultivator and producer of dried flower and medicinal-grade cannabis extracts, PharmaCielo
Read full article
Feb 02, 2023 06:30 ET
PharmaCielo Announces Continued Progress on Efficiency Initiatives to Accelerate Profitability and Intention to Amend Warrant Terms
Steady progress against the efficiency plans initiated in mid-2021 with the transition to the current senior management team. Expects a reduction in its annualized fixed costs by approximately 25% compared to 2022 as a result of these ongoing efforts.The Company is focused on consistently reducing expenses and improving efficiency to facilitate a rapid transition to a cash flow positive position as its revenue continues to grow.Intends to amend the terms of 2,823,750 common share purchase Warrants, reducing the exercise price from C$1.44 to C$0.65 per Common Share.TORONTO and RIONEGRO, Colom
Read full article
See more news stories

Valuation Ratios

Price to Sales - TTM
Price to Book - most recent quarter
Price to Cash Flow per share - TTM
Price to Free Cash Flow per share - TTM
See all valuations

Short Report

DateNumber of Shares ShortedNet Change
Mar 15, 202349,85620,150
Feb 28, 202329,706-17,553
Feb 15, 202347,259-14,744
See Short Report

Business Summary

Sector:  Healthcare Industry:  Pharmaceuticals

PharmaCielo Ltd. is a Canada-based company, which is focused on ethical and sustainable processing and supplying of all natural, pharmaceutical-grade medical cannabis products to channel distributors. The Company through its subsidiary, PharmaCielo Colombia Holdings S.A.S. (PharmaCielo Colombia), cultivates, produces and distributes both tetrahydrocannabinol (THC) and cannabidiol (CBD) medicinal cannabis extracts. The Company's Good Agricultural and Collection Practices (GACP)-certified cultivation takes place on approximately 12 hectares of open-air greenhouses and 2000 square meter (m2) of processing and manufacturing facilities. With four full crops per year, the Company produces approximately 500,000 kg of flower annually. The Company delivers a complete range of medicinal cannabis oil, distillates and isolates for business-to-business (B2B) customers worldwide, including full spectrum, broad spectrum, pure CBD isolates, water-soluble cannabinoids and customized extracts.

See business summary



Search (past week) for $PCLO.CA PCLO.V

  • No tweets found